FDA grants priority review to Kyprolis and approves label update for Zytiga

30 March 2015
fda-big

The US Food and Drug Administration has granted priority review for Kyprolis (carfilzomib) from Amgen (Nasdaq: AMGN) and has approved a label update for Zytiga (abiraterone acetate) from Janssen, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ).

The FDA accepted the supplemental New Drug Application of Kyprolis for injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. This sNDA is designed to support the conversion of accelerated approval to full approval, and expand the current indication for Kyprolis. It has a Prescription Drug User Fee Act target action date of July 26, 2015.

Kyprolis is currently approved by the FDA for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of completion of the last therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical